Astellas Pharma: China NMPA approves VYLOY for advanced gastric/gastroesophageal junction cancer

(RTTNews) – Astellas Pharma Inc. (ALPMY, ALPMY) announced that the China Nationwide Clinical Merchandise Administration is using VYLOY (zolbetuximab), along with fluoropyrimidine-platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2) -unwanted gastric or adenocarcinoma of the gastroesophageal junction (GEJ), whose tumors are claudin (CLDN) 18.2 specified.

Zolbetuximab is the first current NMPA monoclonal antibody to target gastric tumor cells expressing the CLDN18.2 biomarker.

Astellas points out that it has already reflected the impact of the NMPA approval of zolbetuximab in its cash forecast for the unique fiscal year ending March 31, 2025.

Consult rttnews.com for more such medical details.

The views and opinions expressed herein are those of the creator and do not necessarily reflect those of Nasdaq, Inc.